查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1632594

全球生技药品监管提交外包市场：市场规模、份额和趋势分析（按服务、按阶段、按方式、按服务和阶段、按方式和服务、按地区、按细分市场，2025-2030 年）

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service (Regulatory Consulting), By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

生技药品监管适用性外包市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，全球生技药品监管应用外包市场预计到 2030 年将达到 36.9 亿美元，2025 年至 2030 年的复合年增长率为 9.06%。

生物製药公司的全球化是推动市场整体需求的主要成长要素之一。亚太地区、拉丁美洲、中东和非洲的新兴市场具有较低的产品开发和製造成本、优惠的税收制度、相对低成本的技术纯熟劳工和良好监管的市场。上述因素使得该区域市场对生物製药公司来说具有外包和扩张的吸引力，刺激了对监管服务的需求。此外，新兴国家拥有 EMA 和/或 FDA 批准的设施预计将吸引更多的外国投资，这反过来又会增加对法律代表和监管咨询服务等监管服务的需求。

新兴国家正在进行的临床实验的数量大幅增加。这是因为与美国等新兴经济体相比，这些地区拥有熟练劳动力、先进技术和基础设施，且成本相对较低，预计将刺激这些地区对临床实验申请和产品註册等监管服务的需求。新兴国家占全球临床实验申请总量的30.0%以上，预计未来几年这一份额将会增加，进而促进市场的成长。

一些生物製药公司正专注于其核心竞争力，并外包非核心功能以提高生产力和业务效率。这些公司在遵守国际法规方面面临许多挑战，这可能既耗时又繁琐。因此，在可行的时间内以合理的成本将新型分子推向市场的竞争可能会推动对服务提供者的需求。此外，许多不具备内部能力的中小型生物製药公司正在转向外包其监管业务，这估计将对行业进步产生积极影响。

生物相似药、孤儿药、个人化药物和自适应试验设计市场的成长预计将推动这些领域对监管业务的需求。随着多家公司向新领域扩张，对具有监管经验和遵守法规要求的熟练服务供应商的需求也日益增加。政府资助的罕见疾病药物研发大幅增加，尤其是在新兴经济体。 Simulect、 Vectibix、 Mircera和 Kineret 等生技药品的专利到期，增加了对生物相似药的需求和发展，从而增加了该领域对监管服务的需求。

生技药品监管适用性外包市场：分析概述

  • 2024 年，监管文件撰写和出版领域占据了最大的市场占有率。该领域的高速成长是由于生技药品越来越复杂，需要准确全面的文件记录，严格的国际监管要求要求全面提交，以及需要专业知识来确保合规性。基因疗法和生物仿製药等生技药品的快速创新步伐需要对不断发展的法规有最新的了解，这有望推动整体市场的成长。
  • 临床阶段部分将在 2024 年占据最大份额。该部门收益的强劲成长归功于过去几年临床实验报名数量的增加。
  • 单株抗体 (mAb) 部分在 2024 年占据了最大的收益占有率。该领域的成长得益于 mAb 技术的快速进步，包括新颖的递送方法和治疗目标，这需要更新和精确的监管策略，从而带来市场的整体成长潜力。
  • 亚太地区生技药品监管申请外包市场预计将在 2024 年占据最大的收益占有率，为 40.94%，并在预测期内以最快的复合年增长率成长。

目录

第一章 分析方法及范围

第 2 章执行摘要

第 3 章生技药品监管适用性外包市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 技术进步
    • 使用现有和新技术以及推荐工具
    • 区分内部工具和广泛使用的工具
    • 关键技术支柱
    • 巨量资料与分析
    • RTP、文字处理、分析
    • 音讯和视讯分析
    • 物联网 (IoT)
    • 人工智慧工具
  • 定价模式分析
  • 临床实验数量分析（2024 年）
    • 各地区临床实验总数（2024 年）
    • 各阶段临床实验总数（2024 年）
    • 依研究设计分類的临床实验总数（2024 年）
    • 按主要治疗领域分類的临床实验总数（2024 年）
  • 市场分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影响分析

第 4 章生技药品监管适用性外包市场估计与趋势分析（按服务）

  • 细分仪表板
  • 全球生技药品监管适用性外包市场：趋势分析
  • 全球生技药品监管适用性外包市场：按服务类型分類的市场规模和趋势分析（2018-2030 年）
    • 监理咨询
    • 法律代表
    • 监管文件的撰写和发布
    • 产品註册和临床实验申请
    • 监管提交
    • 监管业务
    • 其他服务

第 5 章生技药品监管适用性外包市场估计与趋势分析（分阶段）

  • 细分仪表板
  • 全球生技药品监管适用性外包市场：趋势分析
  • 全球生技药品监管适用性外包市场：市场规模与趋势分析（按阶段划分）（2018-2030 年）
    • 临床前
    • 临床

第六章生技药品监管适用性外包市场估计与趋势分析

  • 细分仪表板
  • 全球生技药品监管适用性外包市场：趋势分析
  • 全球生技药品监管适用性外包市场：按模式分類的市场规模和趋势分析（2018-2030 年）
  • 单株抗体（mAb）
  • 重组蛋白
  • 疫苗
  • 细胞和基因治疗
  • 生物相似药
  • 其他的

第 7生技药品。

  • 细分仪表板
  • 全球生技药品监管适用性外包市场：趋势分析
  • 全球生技药品监管适用性外包市场：按阶段和服务分類的市场规模和趋势分析（2018-2030 年）
    • 临床前
    • 临床

第 8 章生技药品监管适用性外包市场估计和趋势分析（按阶段和模式）

  • 细分仪表板
  • 全球生技药品监管适用性外包市场：趋势分析
  • 全球生技药品监管适用性外包市场：市场规模和趋势分析（按模式和阶段）（2018-2030 年）
    • 临床前
    • 临床

第 9 章生技药品监管适用性外包市场估计和趋势分析（按服务和模式）

  • 细分仪表板
  • 全球生技药品监管适用性外包市场：趋势分析
  • 全球生技药品监管适用性外包市场：市场规模和趋势分析、按服务和模式（2018-2030 年）
    • 单株抗体（mAb）
    • 重组蛋白
    • 疫苗
    • 细胞和基因治疗
    • 生物相似药
    • 其他的

第 10生技药品。

  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十一章 竞争格局

  • 市场参与企业分类
    • 市场领导
    • 新兴企业
  • 竞争市场占有率/估值分析（2024 年）
  • 公司简介
    • Lonza AG
    • Wuxi Apptec Inc.
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • Freyrsolutions
    • Catalent Inc.
    • Piramal Group
    • AGC Biologics
    • ICON Plc.
Product Code: GVR-4-68040-369-4

Biologics Regulatory Affairs Outsourcing Market Growth & Trends:

The global biologics regulatory affairs outsourcing market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 9.06% from 2025 to 2030, according to a new report by Grand View Research, Inc. Globalization of biopharmaceutical companies is one of the major growth drivers boosting overall market demand. Emerging markets of Asia Pacific, Latin America, and MEA regions offer low product development & manufacturing costs, tax benefits, and availability of skilled labor at relatively low costs with supportive regulations. The abovementioned factors have made the regional markets attractive prospects in terms of outsourcing and expansion for biopharmaceutical companies, thereby stimulating the demand for regulatory services. Furthermore, the presence of EMA- and/or FDA-approved facilities in emerging economies is anticipated to increase foreign investments in the country and the demand for regulatory services, such as legal representation and regulatory consulting services.

A significant increase has been witnessed in the number of clinical trials conducted in emerging economies. This can be attributed to the availability of skilled labor, advanced technologies, and infrastructure facilities at relatively lower costs than developed economies such as the U.S., which is expected to stimulate the demand for regulatory services such as clinical trial applications & product registrations in these regions. Emerging economies contribute to more than 30.0% of total clinical trial applications submitted across the globe, and the share is expected to increase over the coming years, contributing to market growth.

Several biopharmaceutical companies are focusing on their core competencies and outsourcing noncore functions to increase their productivity & operational efficiency. These companies face several challenges with regard to complying with global regulations, which can be a lengthy and tedious process. Thus, the race to launch a novel molecule in the market in a feasible timeline and at a reasonable cost will likely propel the demand for service providers. Furthermore, many small- and medium-scale biopharma companies lacking in-house capabilities are inclined towards outsourcing regulatory affairs, which is estimated to positively influence the industry's progression.

Growth in markets for biosimilars, orphan drugs, personalized medicines, adaptive trial designs, and others is projected to boost the demand for regulatory specialization in these areas. As several companies expand into new avenues, the increasing need for skilled service providers with experience in regulations leads to the necessity to comply with regulations. Government support, especially in developed economies, has significantly increased the development of orphan drugs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services in this segment.

Biologics Regulatory Affairs Outsourcing Market Report Highlights:

  • The regulatory writing & publishing segment held the largest market share in 2024. The high segment growth is owing to the increasing complexity of biologics requiring precise and comprehensive documentation, stringent global regulatory requirements demanding thorough submissions, and the need for specialized expertise to ensure compliance. The rapid pace of innovation in biologics, such as gene therapies and biosimilars, necessitates up-to-date knowledge of evolving regulations is anticipated overall market growth
  • The clinical phase segment accounted for the largest share in 2024. The high segmental revenue growth can be attributed to the increasing number of clinical trial registrations over the past few years
  • The monoclonal antibodies (mAbs) segment accounted for the largest revenue share in 2024. The segmental growth is owing to rapid advancements in mAb technology, including novel delivery methods and therapeutic targets, which require updated and precise regulatory strategies leading to overall market growth potential
  • The Asia Pacific biologics regulatory affairs outsourcing market held the largest revenue share of 40.94% in 2024 and is expected to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1:
    • 1.10.2. Objective - 2:
    • 1.10.3. Objective - 3:
    • 1.10.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biologics Regulatory Affairs Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Number of Clinical Trials
      • 3.2.1.2. Increasing Adoption of the Personalized Medicine and Novel Therapeutics
      • 3.2.1.3. Rising R&D Investment in the Healthcare Industry
      • 3.2.1.4. Advancements in the Regulatory Affairs Market
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Managing Relationships
  • 3.3. Technological Advancements
    • 3.3.1. Existing and Emerging Use of Technology and Preferred Tools
    • 3.3.2. Differentiating In-House Tools Vs Widely Available
    • 3.3.3. Key Technology Pillars
      • 3.3.3.1. Digital Transformation and Data Integrity
      • 3.3.3.2. Artificial Intelligence, Machine Learning/Automation
      • 3.3.3.3. Data Analysis and Predictive Modeling
      • 3.3.3.4. Automation of Routine Tasks
      • 3.3.3.5. Compliance Monitoring
      • 3.3.3.6. Discovery and Development
      • 3.3.3.7. Regulatory Guidelines Related to AI/ML
    • 3.3.4. Big Data and Analytics
    • 3.3.5. RTP, Text Processing and Analytics
    • 3.3.6. Speech and Video Analytics
    • 3.3.7. IoT (Internet Of Things)
    • 3.3.8. AI Tools
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2024
    • 3.5.1. Total Number of Clinical Trials, by Region (2024)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2024)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2024)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Biologics Regulatory Affairs Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 4.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
    • 4.3.1. Regulatory Consulting
      • 4.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.2. Strategy & Development Planning
        • 4.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.3. QA Consulting
        • 4.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.4. Agent Services
        • 4.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.5. Others
        • 4.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Legal Representation
      • 4.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Regulatory Writing & Publishing
      • 4.3.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Product Registration & Clinical Trial Applications
      • 4.3.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Regulatory Submissions
      • 4.3.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.6. Regulatory Operations
      • 4.3.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.3.7. Other Services
      • 4.3.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biologics Regulatory Affairs Outsourcing Market: Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 5.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
    • 5.3.1. Preclinical
      • 5.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 5.3.2. Clinical
      • 5.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.2. Phase I
        • 5.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.3. Phase II
        • 5.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.4. Phase III
        • 5.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 5.3.2.5. Phase IV
        • 5.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biologics Regulatory Affairs Outsourcing Market: Modality Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 6.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
  • 6.4. Monoclonal Antibodies (mAbs)
    • 6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.5. Recombinant Proteins
    • 6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.6. Vaccines
    • 6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.7. Cell & Gene Therapies
    • 6.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.8. Biosimilars
    • 6.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biologics Regulatory Affairs Outsourcing Market: Phase by Service Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 7.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Service, 2018 to 2030 (USD Million)
    • 7.3.1. Preclinical
      • 7.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.2. Regulatory Consulting
        • 7.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.3. Legal Representation
        • 7.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.4. Regulatory Writing & Publishing
        • 7.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.5. Product Registration & Clinical Trial Applications
        • 7.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.6. Regulatory Submissions
        • 7.3.1.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.7. Regulatory Operations
        • 7.3.1.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.1.8. Other Services
        • 7.3.1.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 7.3.2. Clinical
      • 7.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.2. Regulatory Consulting
        • 7.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.3. Legal Representation
        • 7.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.4. Regulatory Writing & Publishing
        • 7.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.5. Product Registration & Clinical Trial Applications
        • 7.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.6. Regulatory Submissions
        • 7.3.2.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.7. Regulatory Operations
        • 7.3.2.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 7.3.2.8. Other Services
        • 7.3.2.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biologics Regulatory Affairs Outsourcing Market: Phase by Modality Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 8.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Modality, 2018 to 2030 (USD Million)
    • 8.3.1. Preclinical
      • 8.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.2. Monoclonal Antibodies (mAbs)
        • 8.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.3. Recombinant Proteins
        • 8.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.4. Vaccines
        • 8.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.5. Cell & Gene Therapies
        • 8.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.6. Biosimilars
        • 8.3.1.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.1.7. Others
        • 8.3.1.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.3.2. Clinical
      • 8.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.2. Monoclonal Antibodies (mAbs)
        • 8.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.3. Recombinant Proteins
        • 8.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.4. Vaccines
        • 8.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.5. Cell & Gene Therapies
        • 8.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.6. Biosimilars
        • 8.3.2.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 8.3.2.7. Others
        • 8.3.2.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 9. Biologics Regulatory Affairs Outsourcing Market: Modality by Service Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
  • 9.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Modality by Service, 2018 to 2030 (USD Million)
    • 9.3.1. Monoclonal Antibodies (mAbs)
      • 9.3.1.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.2. Regulatory Consulting
        • 9.3.1.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.3. Legal Representation
        • 9.3.1.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.4. Regulatory Writing & Publishing
        • 9.3.1.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.5. Product Registration & Clinical Trial Applications
        • 9.3.1.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.6. Regulatory Submissions
        • 9.3.1.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.7. Regulatory Operations
        • 9.3.1.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.1.8. Other Services
        • 9.3.1.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.2. Recombinant Proteins
      • 9.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.2. Regulatory Consulting
        • 9.3.2.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.3. Legal Representation
        • 9.3.2.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.4. Regulatory Writing & Publishing
        • 9.3.2.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.5. Product Registration & Clinical Trial Applications
        • 9.3.2.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.6. Regulatory Submissions
        • 9.3.2.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.7. Regulatory Operations
        • 9.3.2.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.2.8. Other Services
        • 9.3.2.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.3. Vaccines
      • 9.3.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.2. Regulatory Consulting
        • 9.3.3.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.3. Legal Representation
        • 9.3.3.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.4. Regulatory Writing & Publishing
        • 9.3.3.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.5. Product Registration & Clinical Trial Applications
        • 9.3.3.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.6. Regulatory Submissions
        • 9.3.3.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.7. Regulatory Operations
        • 9.3.3.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.3.8. Other Services
        • 9.3.3.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.4. Cell & Gene Therapies
      • 9.3.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.2. Regulatory Consulting
        • 9.3.4.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.3. Legal Representation
        • 9.3.4.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.4. Regulatory Writing & Publishing
        • 9.3.4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.5. Product Registration & Clinical Trial Applications
        • 9.3.4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.6. Regulatory Submissions
        • 9.3.4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.7. Regulatory Operations
        • 9.3.4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.4.8. Other Services
        • 9.3.4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.5. Biosimilars
      • 9.3.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.2. Regulatory Consulting
        • 9.3.5.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.3. Legal Representation
        • 9.3.5.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.4. Regulatory Writing & Publishing
        • 9.3.5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.5. Product Registration & Clinical Trial Applications
        • 9.3.5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.6. Regulatory Submissions
        • 9.3.5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.7. Regulatory Operations
        • 9.3.5.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.5.8. Other Services
        • 9.3.5.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 9.3.6. Others
      • 9.3.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.2. Regulatory Consulting
        • 9.3.6.2.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.3. Legal Representation
        • 9.3.6.3.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.4. Regulatory Writing & Publishing
        • 9.3.6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.5. Product Registration & Clinical Trial Applications
        • 9.3.6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.6. Regulatory Submissions
        • 9.3.6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.7. Regulatory Operations
        • 9.3.6.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
      • 9.3.6.8. Other Services
        • 9.3.6.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 10. Biologics Regulatory Affairs Outsourcing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Framework
      • 10.5.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Framework
      • 10.5.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Framework
      • 10.5.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Framework
      • 10.5.5.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Framework
      • 10.5.6.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Framework
      • 10.5.7.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Framework
      • 10.5.8.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Framework
      • 10.5.9.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Framework
      • 10.6.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.3. Japan
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Framework
      • 10.6.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Framework
      • 10.6.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Framework
      • 10.6.5.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Framework
      • 10.6.6.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Framework
      • 10.6.7.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Framework
      • 10.7.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Framework
      • 10.7.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Framework
      • 10.8.2.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Framework
      • 10.8.3.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Framework
      • 10.8.4.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Framework
      • 10.8.5.4. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Competitive Market share/Assessment Analysis, 2024
  • 11.3. Company Profiles
    • 11.3.1. Lonza AG
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Wuxi Apptec Inc.
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Thermo Fisher Scientific Inc.
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Eurofins Scientific SE
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Freyrsolutions
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Catalent Inc.
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Piramal Group
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. AGC Biologics
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. ICON Plc.

List of Tables

  • Table. 1 List of Secondary Sources
  • Table. 2 List of Abbreviations
  • Table. 3 Global Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 4 Global Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 5 Global Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 6 Global Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 7 Global Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 8 Global Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 9 Global Biologics Regulatory Affairs Outsourcing, by Region, 2018 - 2030 (USD Million)
  • Table. 10 North America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 11 North America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 12 North America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 13 North America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 14 North America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 15 North America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 16 North America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 17 U.S. Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 18 U.S. Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 19 U.S. Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 20 U.S. Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 21 U.S. Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 22 U.S. Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 23 Canada Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 24 Canada Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 25 Canada Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 26 Canada Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 27 Canada Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 28 Canada Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 29 Mexico Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 30 Mexico Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 31 Mexico Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 32 Mexico Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 33 Mexico Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 34 Mexico Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 35 Europe Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 36 Europe Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 37 Europe Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 38 Europe Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 39 Europe Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 40 Europe Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 41 Europe Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 42 Germany Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 43 Germany Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 44 Germany Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 45 Germany Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 46 Germany Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 47 Germany Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 48 UK Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 49 UK Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 50 UK Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 51 UK Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 52 UK Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 53 UK Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 54 France Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 55 France Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 56 France Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 57 France Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 58 France Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 59 France Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 60 Italy Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 61 Italy Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 62 Italy Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 63 Italy Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 64 Italy Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 65 Italy Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 66 Spain Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 67 Spain Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 68 Spain Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 69 Spain Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 70 Spain Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 71 Spain Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 72 Denmark Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 73 Denmark Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 74 Denmark Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 75 Denmark Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 76 Denmark Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 77 Denmark Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 78 Sweden Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 79 Sweden Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 80 Sweden Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 81 Sweden Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 82 Sweden Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 83 Sweden Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 84 Norway Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 85 Norway Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 86 Norway Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 87 Norway Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 88 Norway Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 89 Norway Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 90 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 91 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 92 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 93 Asia Pacific Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 94 Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 95 Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 96 Asia Pacific Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 97 China Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 98 China Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 99 China Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 100 China Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 101 China Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 102 China Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 103 Japan Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 104 Japan Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 105 Japan Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 106 Japan Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 107 Japan Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 108 Japan Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 109 India Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 110 India Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 111 India Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 112 India Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 113 India Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 114 India Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 115 South Korea Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 116 South Korea Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 117 South Korea Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 118 South Korea Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 119 South Korea Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 120 South Korea Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 121 Australia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 122 Australia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 123 Australia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 124 Australia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 125 Australia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 126 Australia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 127 Thailand Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 128 Thailand Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 129 Thailand Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 130 Thailand Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 131 Thailand Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 132 Thailand Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 133 Latin America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 134 Latin America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 135 Latin America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 136 Latin America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 137 Latin America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 138 Latin America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 139 Latin America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 140 Brazil Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 141 Brazil Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 142 Brazil Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 143 Brazil Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 144 Brazil Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 145 Brazil Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 146 Argentina Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 147 Argentina Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 148 Argentina Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 149 Argentina Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 150 Argentina Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 151 Argentina Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 152 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 153 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 154 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 155 Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 156 Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 157 Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 158 Middle East & Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 159 South Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 160 South Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 161 South Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 162 South Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 163 South Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 164 South Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 165 Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 166 Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 167 Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 168 Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 169 Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 170 Saudi Arabia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 171 UAE Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 172 UAE Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 173 UAE Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 174 UAE Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 175 UAE Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 176 UAE Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
  • Table. 177 Kuwait Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
  • Table. 178 Kuwait Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
  • Table. 179 Kuwait Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
  • Table. 180 Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
  • Table. 181 Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
  • Table. 182 Kuwait Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biologics Regulatory Affairs Outsourcing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biologics Regulatory Affairs Outsourcing, for Strategy & Development Planning, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biologics Regulatory Affairs Outsourcing, for QA Consulting, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biologics Regulatory Affairs Outsourcing, for Agent Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biologics Regulatory Affairs Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 18 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 19 Global Biologics Regulatory Affairs Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biologics Regulatory Affairs Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biologics Regulatory Affairs Outsourcing, for Preclinical, 2018 - 2030 (USD Million)
  • Fig. 23 Global Biologics Regulatory Affairs Outsourcing, for Clinical, 2018 - 2030 (USD Million)
  • Fig. 24 Global Biologics Regulatory Affairs Outsourcing, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biologics Regulatory Affairs Outsourcing, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biologics Regulatory Affairs Outsourcing, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 27 Global Biologics Regulatory Affairs Outsourcing, for Phase IV, 2018 - 2030 (USD Million)
  • Fig. 28 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 29 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 30 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 31 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 32 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 33 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 34 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Other Services, 2018 - 2030 (USD Million)
  • Fig. 35 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 36 Global Biologics Regulatory Affairs Outsourcing, for Clinical Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 37 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 38 Global Biologics Regulatory Affairs Outsourcing, for Clinical Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 39 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 40 Global Biologics Regulatory Affairs Outsourcing, for Clinical Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 41 Global Biologics Regulatory Affairs Outsourcing, for Clinical Other Services, 2018 - 2030 (USD Million)
  • Fig. 42 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 43 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 44 Global Biologics Regulatory Affairs Outsourcing, for Vaccines, 2018 - 2030 (USD Million)
  • Fig. 45 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 46 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 47 Global Biologics Regulatory Affairs Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 48 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 49 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 50 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Vaccines, 2018 - 2030 (USD Million)
  • Fig. 51 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 52 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 53 Global Biologics Regulatory Affairs Outsourcing, for Preclinical Others, 2018 - 2030 (USD Million)
  • Fig. 54 Global Biologics Regulatory Affairs Outsourcing, for Clinical Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 55 Global Biologics Regulatory Affairs Outsourcing, for Clinical Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 56 Global Biologics Regulatory Affairs Outsourcing, for Clinical Vaccines, 2018 - 2030 (USD Million)
  • Fig. 57 Global Biologics Regulatory Affairs Outsourcing, for Clinical Cell & Gene Therapies, 2018 - 2030 (USD Million)
  • Fig. 58 Global Biologics Regulatory Affairs Outsourcing, for Clinical Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 59 Global Biologics Regulatory Affairs Outsourcing, for Clinical Others, 2018 - 2030 (USD Million)
  • Fig. 60 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 61 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 62 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 63 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 64 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 65 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 66 Global Biologics Regulatory Affairs Outsourcing, for Monoclonal Antibodies (mAbs) Other Services, 2018 - 2030 (USD Million)
  • Fig. 67 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 68 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 69 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 70 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 71 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 72 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 73 Global Biologics Regulatory Affairs Outsourcing, for Recombinant Proteins Other Services, 2018 - 2030 (USD Million)
  • Fig. 74 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 75 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 76 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 77 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 78 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 79 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 80 Global Biologics Regulatory Affairs Outsourcing, for Vaccines Other Services, 2018 - 2030 (USD Million)
  • Fig. 81 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 82 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 83 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 84 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 85 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 86 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 87 Global Biologics Regulatory Affairs Outsourcing, for Cell & Gene Therapies Other Services, 2018 - 2030 (USD Million)
  • Fig. 88 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 89 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 90 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 91 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 92 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 93 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 94 Global Biologics Regulatory Affairs Outsourcing, for Biosimilars Other Services, 2018 - 2030 (USD Million)
  • Fig. 95 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 96 Global Biologics Regulatory Affairs Outsourcing, for Others Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 97 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 98 Global Biologics Regulatory Affairs Outsourcing, for Others Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 99 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 100 Global Biologics Regulatory Affairs Outsourcing, for Others Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 101 Global Biologics Regulatory Affairs Outsourcing, for Others Other Services, 2018 - 2030 (USD Million)
  • Fig. 102 Regional Outlook, 2023 & 2030
  • Fig. 103 North America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 US Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Canada Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Mexico Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Europe Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Germany Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 UK Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 France Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Italy Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Spain Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Denmark Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Sweden Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Norway Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Asia Pacific Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Japan Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 China Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 India Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Australia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 South Korea Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Thailand Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 Latin America Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Brazil Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Argentina Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 126 Middle East and Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 South Africa Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 128 Saudi Arabia Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 129 UAE Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 130 Kuwait Biologics Regulatory Affairs Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)